View More View Less
  • 1 Department of Infectious Diseases, 1st Department of Internal Medicine, University of Pécs, Pécs, , Hungary
  • | 2 Department of Gastroenterology, 1st Department of Internal Medicine, University of Pécs, Pécs, , Hungary
  • | 3 Department of Medical Microbiology and Immunology, University of Pécs, Pécs, , Hungary
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $784.00

Faecal microbiota transplantation (FMT) has been reported to be effective in treating relapsing of refractory Clostridium difficile infections, although some practical barriers are limiting its widespread use. In this study, our objective was to evaluate the rate of resolution of diarrhea following administration of lyophilized and resolved FMT via a nasogastric (NG) tube. We recruited 19 patients suffered from laboratory-confirmed C. difficile infection. Each of them was treated by lyophilized and resolved inoculum through a NG tube. One participant succumbed following the procedure due to unrelated diseases. Out of 18 cases, 15 patients reportedly experienced a resolution of the symptoms. One patient was treated with another course of antibiotics, and two of the non-responders were successfully retreated with another course of FMT utilizing a lyophilized inoculum. Notably, no significant adverse activities were observed. In accordance to our clinical experiences, a patient will likely benefit from FMT treatment including lyophilized inoculum.

  • 1.

    Hall, I. C., O’Toole, E.: Intestinal flora in newborn infants: With a description of a new pathogenic anaerobe, Bacillus difficile. Am J Dis Child 49, 390 (1935).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Larson, H. E., Price, A. B., Honour, P., Borriello, S. P.: Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet 1, 10631067 (1978).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Carroll, K. C., Bartlett, J. G.: Biology of Clostridium difficile: Implications for epidemiology and diagnosis. Annu Rev Microbiol 65, 501521 (2011).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    O’Donoghue, C., Kyne, L.: Update on Clostridium difficile infection. Curr Opin Gastroenterol 27, 3847 (2011).

  • 5.

    Lo Vecchio, A., Zacur, G. M.: Clostridium difficile infection: An update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol 28, 19 (2012).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Pepin, J., Valiquette, L., Gagnon, S., Routhier, S., Brazeau, I.: Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 102, 27812788 (2007).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Petrella, L. A., Sambol, S. P., Cheknis, A., Nagaro, K., Kean, Y., Sears, P.S., Babakhani, F., Johnson, S., Gerding, D. N.: Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis 55, 351357 (2012).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Austin, M., Mellow, M., Tierney, W. M.: Fecal microbiota transplantation in the treatment of Clostridium difficile infections. Am J Med 127, 479483 (2011).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Youngster, I., Sauk, J., Pindar, C., Wilson, R. G., Kaplan, J. L., Smith, M. B., Alm, E. J., Gevers, D., Russell, G. H., Hohmann, E. L.: Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: A randomized, open-label, controlled pilot study. Clin Infect Dis 58, 15151522 (2011).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F., Tijssen, J. G., Speelman, P., Dijkgraaf, M. G., Keller, J. J.: Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368, 407415 (2013).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Debast, S. B., Bauer, M. P., Kuijper, E. J., European Society of Clinical Microbiology and Infectious Diseases: European Society of Clinical Microbiology and Infectious Diseases update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 20, 126 (2014).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Surawicz, C. M., Brandt, L. J., Binion, D. G., Ananthakrishnan, A. N., Curry, S. R., Gilligan, P. H., McFarland, L. V., Mellow, M., Zuckerbraun, B. S.: Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108, 478498 (2013).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Hamilton, M., Weingardenv, A., Sadowsky, M., Khoruts, A.: Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 107, 761767 (2012).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14.

    Lee, C. H, Steiner, T., Petrof, E. O., Smieja, M., Roscoe, D., Nematallah, A., Weese, J. S., Collins, S., Moayyedi, P., Crowther, M., Ropeleski, M. J, Jayaratne, P., Higgins, D., Li, Y., Rau, N. V, Kim, P. T.: Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: A randomized clinical trial. JAMA 315, 142149 (2016).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Festi, D., Schiumerini, R., Birtolo, C., Marzi, L., Montrone, L., Scaioli, E., Di Biase, A. R., Colecchia, A.: Gut microbiota and its pathophysiology in disease paradigms. Dig Dis 29, 518552 (2011).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Ghoshal, U., Shukla, R., Ghoshal, U., Gwee, K. A., Ng, S. C., Quigley, E. M.: The gut microbiota and irritable bowel syndrome: Friend or foe? Int J Inflamm 2012, 151085 (2012).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Rholke, F., Stollman, F.: Fecal microbiota transplantation in relapsing Clostridium difficile infection. Ther Adv Gastroenterol 516, 403420 (2012).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19.

    Gough, E., Shaikh, H., Manges, A.: Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 53, 9941002 (2011).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    Borody, T. J., Warren, E. F., Leis, M. S., Surace, R., Ashman, O., Siarakas, S.: Bacteriotherapy using fecal flora toying with human motions. J Clin Gastroenterol 38, 475483 (2004).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21.

    Gustaffson, A., Lund-Tonnensen, S., Berstad, A., Midtvedt, T., Norin, E.: Faecal short-chain fatty acids in patients with antibiotic associated diarrhea, before and after fecal enema treatment. Scand J Gastroeneterol 33, 721727 (1998).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 22.

    Gustaffson, A., Berstad, A., Lund-Tonnensen, S., Midtvedt, T., Norin, E.: The effect of fecal enema on five microflora associated characteristics in patients with antibiotic associated diarrhea. Scand J Gastroenterol 34, 580586 (1999).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23.

    Aas, J., Gessert, C., Bakken, J.: Recurrent Clostridium difficile colitis: Case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 36, 580585 (2013).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 24.

    Garborg, K., Waagsbo, B., Stallemo, A., Matre, J., Sundøy, A.: Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhoea. Scand J Infect Dis 42, 857861 (2010).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 25.

    Nieuwdorp, M., van Nood, E., Speelman, P., van Heukelem, H. A., Jansen, J. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F., Keller, J. J.: Treatment of recurrent Clostridium difficile-associated diarrhoea with a suspension of donor faeces. Ned Tijdschr Geneeskd 152, 19271932 (2008).

    • Search Google Scholar
    • Export Citation
  • 26.

    Rubin, T., Gessert, C., Aas, J.: Stool transplantation for older patients with Clostridium difficile infection. J Am Geriatr Soc 57, 2386 (2009).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 27.

    Vigvari, Sz., Nemes, Zs., Vincze, A., Solt, J., Sipos, D., Feiszt, Z., Kappéter, A., Kovács, B., Péterfi, Z.: Experience with fecal microbiota transplantation in the treatment of Clostridium difficile infection. Orv Hetil 155, 17581762 (2014).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28.

    Brandt, L., Aroniadis, O., Mellow, M., Kanatzar, A., Kelly, C., Park, T., Stollman, N., Rohlke, F., Surawicz, C.: Long-term follow-up of colonoscopic fecal microbiota transplant (FMT) for recurrent C. difficile infection (RCDI). Am J Gastroenterol 107, 10791087 (2012).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 29.

    Bakken, J. S., Borody, T., Brandt, L. J., Brill, J. V., Demarco, D. C., Franzos, M. A., Kelly, C., Khoruts, A., Louie, T., Martinelli, L. P., Moore, T. A., Russell, G., Surawicz, C., Fecal Microbiota Transplantation Workgroup: Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 12, 10441049 (2011).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 30.

    Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., Wilcox, M., Society for Healthcare Epidemiology of America, Infectious Diseases Society of America: Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 31, 431455 (2010).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 31.

    Kupletskaya, M. B., Netrusov, A. I.: Viability of lyophilized microorganisms after 50-year storage. Microbiology 80, 850853 (2011).

  • 32.

    Antheunisse, J. Viability of lyophilized microorganisms after storage. Antonie van Leeuwenhoek 39, 243248 (1973).

 

The author instruction is available in PDF.
Please, download the file from HERE

Senior editors

Editor-in-Chief: Prof. Dóra Szabó (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Managing Editor: Dr. Béla Kocsis (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Co-editor: Dr. Andrea Horváth (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Editorial Board

  • Prof. Éva ÁDÁM (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Sebastian AMYES (Department of Medical Microbiology, University of Edinburgh, Edinburgh, UK.)
  • Dr. Katalin BURIÁN (Institute of Clinical Microbiology University of Szeged, Szeged, Hungary; Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary.)
  • Dr. Orsolya DOBAY (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Ildikó Rita DUNAY (Institute of Inflammation and Neurodegeneration, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany; Center for Behavioral Brain Sciences (CBBS), Magdeburg, Germany)
  • Prof. Levente EMŐDY(Department of Medical Microbiology and Immunology, University of Pécs, Pécs, Hungary.)
  • Prof. Anna ERDEI (Department of Immunology, Eötvös Loránd University, Budapest, Hungary, MTA-ELTE Immunology Research Group, Eötvös Loránd University, Budapest, Hungary.)
  • Prof. Éva Mária FENYŐ (Division of Medical Microbiology, University of Lund, Lund, Sweden)
  • Prof. László FODOR (Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, Budapest, Hungary)
  • Prof. József KÓNYA (Department of Medical Microbiology, University of Debrecen, Debrecen, Hungary)
  • Prof. Yvette MÁNDI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Károly MÁRIALIGETI (Department of Microbiology, Eötvös Loránd University, Budapest, Hungary)
  • Prof. János MINÁROVITS (Department of Oral Biology and Experimental Dental Research, University of Szeged, Szeged, Hungary)
  • Prof. Béla NAGY (Centre for Agricultural Research, Institute for Veterinary Medical Research, Budapest, Hungary.)
  • Prof. István NÁSZ (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Kristóf NÉKÁM (Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary.)
  • Dr. Eszter OSTORHÁZI (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Rozália PUSZTAI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Peter L. RÁDY (Department of Dermatology, University of Texas, Houston, Texas, USA)
  • Prof. Éva RAJNAVÖLGYI (Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary)
  • Prof. Ferenc ROZGONYI (Institute of Laboratory Medicine, Semmelweis University, Budapest, Hungary)
  • Prof. Zsuzsanna SCHAFF (2nd Department of Pathology, Semmelweis University, Budapest, Hungary)
  • Prof. Joseph G. SINKOVICS (The Cancer Institute, St. Joseph’s Hospital, Tampa, Florida, USA)
  • Prof. Júlia SZEKERES (Department of Medical Biology, University of Pécs, Pécs, Hungary.)
  • Prof. Mária TAKÁCS (National Reference Laboratory for Viral Zoonoses, National Public Health Center, Budapest, Hungary.)
  • Prof. Edit URBÁN (Department of Medical Microbiology and Immunology University of Pécs, Pécs, Hungary; Institute of Translational Medicine, University of Pécs, Pécs, Hungary.)

 

Editorial Office:
Akadémiai Kiadó Zrt.
Budafoki út 187-187, A/3, H-1117 Budapest, Hungary

Editorial Correspondence:
Acta Microbiologica et Immunologica Hungarica
Institute of Medical Microbiology
Semmelweis University
P.O. Box 370
H-1445 Budapest, Hungary
Phone: + 36 1 459 1500 ext. 56101
Fax: (36 1) 210 2959
E-mail: amih@med.semmelweis-univ.hu

 Indexing and Abstracting Services:

  • Biological Abstracts
  • BIOSIS Previews
  • CAB Abstracts
  • Chemical Abstracts
  • Global Health
  • Index Medicus
  • Index Veterinarius
  • Medline
  • Referativnyi Zhurnal
  • SCOPUS
  • Science Citation Index Expanded
2020  
Total Cites 662
WoS
Journal
Impact Factor
2,048
Rank by Immunology 145/162(Q4)
Impact Factor Microbiology 118/137 (Q4)
Impact Factor 1,904
without
Journal Self Cites
5 Year 0,671
Impact Factor
Journal  0,38
Citation Indicator  
Rank by Journal  Immunology 146/174 (Q4)
Citation Indicator  Microbiology 120/142 (Q4)
Citable 42
Items
Total 40
Articles
Total 2
Reviews
Scimago 28
H-index
Scimago 0,439
Journal Rank
Scimago Immunology and Microbiology (miscellaneous) Q4
Quartile Score Medicine (miscellaneous) Q3
Scopus 438/167=2,6
Scite Score  
Scopus General Immunology and Microbiology 31/45 (Q3)
Scite Score Rank  
Scopus 0,760
SNIP
Days from  225
submission
to acceptance
Days from  118
acceptance
to publication
Acceptance 19%
Rate

2019  
Total Cites
WoS
485
Impact Factor 1,086
Impact Factor
without
Journal Self Cites
0,864
5 Year
Impact Factor
1,233
Immediacy
Index
0,286
Citable
Items
42
Total
Articles
40
Total
Reviews
2
Cited
Half-Life
5,8
Citing
Half-Life
7,7
Eigenfactor
Score
0,00059
Article Influence
Score
0,246
% Articles
in
Citable Items
95,24
Normalized
Eigenfactor
0,07317
Average
IF
Percentile
7,690
Scimago
H-index
27
Scimago
Journal Rank
0,352
Scopus
Scite Score
320/161=2
Scopus
Scite Score Rank
General Immunology and Microbiology 35/45 (Q4)
Scopus
SNIP
0,492
Acceptance
Rate
16%

 

Acta Microbiologica et Immunologica Hungarica
Publication Model Online only Hybrid
Submission Fee none
Article Processing Charge 1100 EUR/article
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription fee 2021 Online subsscription: 652 EUR / 812 USD
Subscription fee 2022 Online subsscription: 662 EUR / 832 USD
Print + online subscription: 740 EUR / 930 USD
Subscription Information Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content.
Purchase per Title Individual articles are sold on the displayed price.

Acta Microbiologica et Immunologica Hungarica
Language English
Size A4
Year of
Foundation
1954
Publication
Programme
2021 Volume 68
Volumes
per Year
1
Issues
per Year
4
Founder Magyar Tudományos Akadémia
Founder's
Address
H-1051 Budapest, Hungary, Széchenyi István tér 9.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 1217-8950 (Print)
ISSN 1588-2640 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jun 2021 2 1 1
Jul 2021 4 0 0
Aug 2021 13 1 2
Sep 2021 9 2 2
Oct 2021 5 0 0
Nov 2021 11 1 1
Dec 2021 0 0 0